The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with ...

Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated ...

Sanofi has chosen US private equity firm Clayton, Dubilier & Rice to advance acquisition talks for its consumer health unit, ...

Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief ...

A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after ...

Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the ...

This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company's drug for ...

Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its ...

Pfizer's former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company's ...

In early-stage trials called dose escalation studies, drug developers usually want to test progressively higher doses of ...